Document Detail

Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
MedLine Citation:
PMID:  11755464     Owner:  NLM     Status:  MEDLINE    
The multidrug resistance (MDR) transporter-proteins P-glycoprotein (Pgp), multidrug resistance protein (MRP) and lung resistance protein (LRP) have been associated with treatment failure. The aim of this study was to investigate prospectively the clinical significance of expression and function of the MDR proteins, considering other prognostic factors, such as age, immunophenotype, and cytogenetics. Mononuclear cells of peripheral blood or bone marrow from 61 patients with de novo acute myelogenous leukemia (AML) were analyzed. The monoclonal antibodies JSB1, MRPm6 and LRP56 were used for expression studies. Accumulation and retention studies were performed using the substrates Daunorubicin, Calcein-AM, Rhodamine-123 and DiOC(2) in the presence or absence of the modifiers Verapamil, Genistein, Probenecid, BIBW22S and PSC833. Induction treatment consisted of a 3+7 combination of Ida/Ara-C for patients < or = 60 years of age and a 3+5 Ida/VP-16 combination per OS for patients >60. MDR function was expressed as the ratio of mean fluorescence intensity substrate in the presence of modifier over the substrate alone (resistance index, RI). Patients with advanced age, low CD15 expression and high RI for accumulation of DiOC(2) in the presence of BIBW22S had significantly lower complete remission (CR) rates. No factor was prognostic for event-free survival analysis, which was limited to remitters only. Overall survival was shorter in patients with advanced age, poor prognosis cytogenetics, high CD7 expression, and high RI for Daunorubicin efflux modulated by Verapamil. These results suggest that MDR transporter-proteins have a limited role in the treatment failure of patients treated with Idarubicin-based regimens.
Apostolia Maria Tsimberidou; George Paterakis; George Androutsos; Nikolaos Anagnostopoulos; Athanasios Galanopoulos; Themistoklis Kalmantis; John Meletis; Yiannis Rombos; Alexandros Sagriotis; Argyrios Symeonidis; Maria Tiniakou; Nikolaos Zoumbos; Xenophon Yataganas
Related Documents :
11678324 - Myocytes' apoptosis and proliferation in endomyocardial biopsy as prognostic factors in...
12796384 - Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma.
20583424 - Gabarap is overexpressed in colorectal carcinoma and correlates with shortened patient ...
9210714 - Vascular endothelial growth factor expression in early stage ovarian carcinoma.
19949954 - The impact of paratracheal lymph node metastasis in squamous cell carcinoma of the hypo...
3214044 - Intensified chemotherapy for childhood lymphoblastic leukemia: modifications and result...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia research     Volume:  26     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2001-12-28     Completed Date:  2002-03-27     Revised Date:  2006-10-03    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  143-54     Citation Subset:  IM    
Department of Internal Medicine, The University of Athens, Athens 11527, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Age Factors
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow Transplantation
Calcium Channel Blockers / pharmacology
Carbocyanines / metabolism
Combined Modality Therapy
Cytarabine / administration & dosage
Daunorubicin / metabolism
Disease-Free Survival
Drug Resistance, Multiple / genetics*
Drug Resistance, Neoplasm / genetics*
Enzyme Inhibitors / pharmacology
Fluoresceins / metabolism
Fluorescent Dyes / metabolism
Genistein / pharmacology
Idarubicin / administration & dosage
Leukemia, Myeloid / drug therapy,  genetics,  metabolism*,  mortality,  therapy
Middle Aged
Multidrug Resistance-Associated Proteins / biosynthesis,  genetics,  physiology*
Neoplasm Proteins / biosynthesis,  genetics,  physiology*
P-Glycoprotein / biosynthesis,  genetics,  physiology*
Probenecid / pharmacology
Prospective Studies
Rhodamine 123 / metabolism
Survival Analysis
Tumor Cells, Cultured / metabolism
Vault Ribonucleoprotein Particles / biosynthesis,  genetics,  physiology*
Verapamil / pharmacology
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Carbocyanines; 0/Enzyme Inhibitors; 0/Fluoresceins; 0/Fluorescent Dyes; 0/Multidrug Resistance-Associated Proteins; 0/Neoplasm Proteins; 0/P-Glycoprotein; 0/Vault Ribonucleoprotein Particles; 0/major vault protein; 0/multidrug resistance-associated protein 1; 147-94-4/Cytarabine; 148504-34-1/calcein AM; 20830-81-3/Daunorubicin; 37069-75-3/3,3'-diethyloxacarbocyanine; 446-72-0/Genistein; 52-53-9/Verapamil; 57-66-9/Probenecid; 58957-92-9/Idarubicin; 62669-70-9/Rhodamine 123

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after alloge...
Next Document:  Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTL...